TauC3 Biologics Ltd
Therapeutics
TauC3 Biologics is focused on the development of innovative high precision immunotherapy for the treatment of the devastating neurodegenerative diseases known as tauopathies, particularly tau-related frontotemporal dementia (FTD-tau) and progressive supranuclear palsy (PSP).
Contact: Daniel G. Chain, PhD, President and CEO
dchain@tauc3bio.com
See other Therapeutics organisations
-
AKL Research & Development Ltd.'s focus is in inflammatory diseases, particularly those related to dysregulation of the innate immune system. -
Antabio is a private biopharmaceutical company developing a broad pipeline of novel antibacterial treatments focused on drug-resistant life threatening infections. ... -
To 2014 - Antikor Biopharma Limited was established in mid-2014 following the restructuring of PhotoBiotics Limited. The new Company retains ... -
Autifony Therapeutics aims to develop new drugs to treat serious disorders of the central nervous system using pioneering science
Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.
Learn moreCopyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.